Navigation Links
Improved culture system for hepatitis C virus infection
Date:7/15/2008

A University of California, San Diego School of Medicine researcher has developed the first tissue culture of normal, human liver cells that can model infection with the Hepatitis C virus (HCV) and provide a realistic environment to evaluate possible treatments. The novel cell line, described in the July 16 issue of PLoS ONE, will allow pharmaceutical companies to effectively test new drug candidates or possible vaccines for the HCV infection, which afflicts about 170 million people worldwide. Currently, there is no animal model that is effective for testing such therapies.

Assistant Professor of Medicine Martina Buck, Ph.D., researcher at UC San Diego's Department of Medicine and Moores UCSD Cancer Center developed the novel culture system, which mimics the biology of HCV infection in humans.

"This is the first efficient and consistent model system for HCV to be developed," said Buck, adding that it will now enable researchers not only to conduct mechanistic experiments in culture, such as blocking the virus pathways, but also to more effectively screen possible therapies for HCV. "There is a need for new treatments, and for development of a possible vaccine for HCV. Now we have a model system to support work by investigators in this area."

Currently, there is only a single treatment for HCV, PEG- interferon-α. The drug combination has an average response rate of about 50 percent in HCV cases, but it is much lower than that, closer to 20 percent, in individuals with liver cirrhosis. It can also cause severe flu-like side effects. Approximately 10,000 deaths due to cirrhosis of the liver and several thousand more from liver cancer are attributed to HCV infection in the United States each year.

The HCV life cycle is only partially understood because, until now, it has not been possible to efficiently infect normal human hepatocytes, or liver cells, in culture. According to Buck, the valuable Huh-7 system
'/>"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Page: 1 2

Related biology technology :

1. Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety
2. Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments
3. Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin
4. Improved wettability of carbon nanotubes opens the door to new possibilities
5. Diagnostic Turnaround Improved by 600% Through Interoperability
6. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
7. New Robotic Imaging Technology Holds Promise of Improved Cancer Care
8. Improved governance needed to realize nanotechs benefits
9. Sophisticated soil analysis for improved land use
10. China Kangtai Cactus Biotech Announces Improved Milk Production in Cows From Companys Cactus Cattle Feed
11. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , September 2, 2015 ... BOLT) ("BioLight" or the "Company"), a firm that ... ophthalmology and cancer diagnostics, announced today that presentations ... glaucoma will be delivered at the Ophthalmology Futures ... European Society of Cataract & Refractive Surgeons ("ESCRS"), ...
(Date:9/2/2015)... ... 02, 2015 , ... Whitehouse Laboratories is excited to announce ... Resources upcoming educational seminar and training session on Extractable & Leachable testing. Featuring ... provide Updates & Case Studies on the Latest Compliance Implications of USP and ...
(Date:9/1/2015)... , September 2, 2015 ... primär auf die Forschung und Entwicklung neuartiger ... Allergien, chronisch-entzündliche Darmerkrankungen und Reizdarm konzentriert, erhält ... Zusage, dass sein neues Medikament patentiert wird. ... das Allergien bei Kindern verhindert und Entzündungen ...
(Date:9/1/2015)... Sept. 1, 2015 Prostate cancer ... in American men. One in seven men will ... new cases are diagnosed annually. That said, not ... a powerful new technique, MRI Fusion Biopsy, to ... cancer lesions, treating only the affected areas and ...
Breaking Biology Technology:Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4
... ST. LOUIS, Oct. 16 ISTO Technologies, Inc., ... data,related to its NuQu(TM) injectable cell-based therapy for ... Canada at the 23rd Annual,Meeting of the North ... of California San Francisco (UCSF) Department of Orthopedics,were ...
... ATLANTA, Oct. 16 CryoLife, Inc. (NYSE: CRY ... that third quarter 2008 financial results will be released ... teleconference call and,live webcast at 10:00 a.m. Eastern Time, ... question and answer session hosted by Steven G.,Anderson, president ...
... The acquisition will solidify China Biologic,s position as the ... -- Company provides preliminary guidance for 2009 of ... $100 million and ... CITY, Shandong, China, Oct. 16 /Xinhua-PRNewswire-FirstCall/ --,China Biologic Products, ...
Cached Biology Technology:Positive Preclinical Data on Cell Therapy for Spinal Disc Repair Presented at 23rd Annual Meeting of the North American Spine Society 2CryoLife Announces Release Date and Teleconference Call Details for Third Quarter 2008 Financial Results 2China Biologic Products Enters Into Agreement to Acquire 35% Interest in Xi'an Huitian Blood Products Co., Ltd. and Introduces Preliminary Guidance for 2009 2China Biologic Products Enters Into Agreement to Acquire 35% Interest in Xi'an Huitian Blood Products Co., Ltd. and Introduces Preliminary Guidance for 2009 3China Biologic Products Enters Into Agreement to Acquire 35% Interest in Xi'an Huitian Blood Products Co., Ltd. and Introduces Preliminary Guidance for 2009 4China Biologic Products Enters Into Agreement to Acquire 35% Interest in Xi'an Huitian Blood Products Co., Ltd. and Introduces Preliminary Guidance for 2009 5
(Date:8/12/2015)... MINNETONKA, Minn. , Aug. 12, 2015   ... that supports the entire spectrum of clinical research, is ... ™ , the company,s comprehensive SaaS-based eClinical technology platform, ... growth during the first two quarters of 2015.   ... and second largest quarters measured by contract value sold ...
(Date:8/10/2015)... and TELTOW, Germany , August 10, ... (SMI), a world leader in Eye Tracking Technology for ... its OEM Eye Tracking Platform for integration into all ... contains reference designs for seamless integration of eye tracking ... reality HMDs and augmented reality smart glasses. Omnivision,s leading ...
(Date:8/5/2015)... 2015 According to a new ... Software, Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, ... Forecast to 2020", published by MarketsandMarkets, defines and segments ... various segments. The global PIAM Market is estimated to ... by 2019, at a CAGR of 14.9 % from ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... DIEGO (August 3, 2009) La Jolla Institute for ... play a role in allergy onset, instead have discovered ... may be important in myeloproliferative diseases and some types ... of disorders characterized by an overproduction of blood cells ...
... organisms evolve from a single cell, a fertilised egg. In ... development is determined. It is dictated by the separation of ... from the remaining cells, which will be responsible for forming ... somatic cell line. Scientists at the Institute for Research in ...
... 2009 The intake of added sugars in the United ... in 1999-2002 as 17% of calories a day. Consuming foods ... or limiting intake of added sugars is an important objective ... 30,000 Americans published in the August 2009 issue of the ...
Cached Biology News:La Jolla Institute discovers novel tumor suppressor 2La Jolla Institute discovers novel tumor suppressor 3Protecting cells from their neighbors 2Race/ethnicity, family income and education associated with sugar consumption 2
... optically clear polystyrene formulation , High antibody-binding ... , Plates are certified for performance ... , Eight-well strips fit snugly in ... in use even if turned upside down ...
...
... StabilZyme SELECT Stabilizer is an aqueous ... and other non-toxic stabilizing chemicals in a ... contains a combination of 0.02% methylisothiazolone and ... SELECT Stabilizer is a diluent and stabilizer ...
... is a bovine protein-free alternative to StabilCoat ... solution that contains non-toxic chemicals in a ... - 7.2, and does not contain a ... of antibodies and other biomolecules that are ...
Biology Products: